NYSE: NVST · Medical Instruments & Supplies
Envista Holdings (NVST) fair value and price range
As of 26 Sep 2026, Faircurve's model values Envista Holdings (NVST) at $23.26 a share. The stock last closed at $23.95, which puts the model's fair value 2.9% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 25 Sep 2026. Envista Holdings Corp.
Faircurve Insights · 26 Sep 2026
Envista Holdings Corporation develops and distributes a comprehensive range of dental solutions.
Faircurve's model found a fair value of $23.26 a share on 26 Sep 2026, the midpoint of 2,000 simulations. The previous run on 15 Aug 2026 gave $32.50, and the fair value moved -28.4%. The model's calibrated range over 63 trading days is $19.51 to $28.36, built from the fair value and calibrated weekly against realised prices, which held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.
The overall quality score for Envista Holdings Corp is 62 out of 100 against comparable companies. Profitability scores 33, with ROIC at 5.2% against a peer median of 7.2%. Earnings quality scores 88 (FCF / net income 2.45x) and growth quality scores 61 (Revenue growth, trailing 8.3%, peer median -3.0%). The model compares Envista Holdings Corp with ICU Medical, Inc., Merit Medical Systems, Inc., AptarGroup, Inc., BioLife Solutions, Inc., LeMaitre Vascular, Inc., and Avantor, Inc.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give NVST?
The calibrated range for NVST over 63 trading days is $19.51 to $28.36. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $16.94 to $31.24. In 47% of the simulations the fair value came out above the price the model ran on.
How does NVST score on business quality?
Envista Holdings's overall quality score is 62 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 33 | 5.2%ROIC | 7.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 88 | 2.45xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 61 | 8.3%Revenue growth, trailing | -3.0% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 95 | 5.4%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 61 | 1.32xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 70 | 2.8 ptsEBITDA margin downside volatility, 5y | 8.5 pts |
How does NVST compare with similar companies?
The companies in medical instruments & supplies closest to Envista Holdings in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ICUI ICU Medical, Inc. | $164.95 | $191.03 | +15.8% | Undervalued |
| MMSI Merit Medical Systems, Inc. | $87.50 | $89.09 | +1.8% | Fairly valued |
| TFX Teleflex Incorporated | $122.07 | $125.37 | +2.7% | Low model confidence |
| ATR AptarGroup, Inc. | $123.87 | $123.36 | -0.4% | Fairly valued |
| XRAY DENTSPLY SIRONA Inc. | $9.40 | $15.20 | +61.7% | Gap wider than 60% |
| BLFS BioLife Solutions, Inc. | $38.49 | $33.70 | -12.4% | Fairly valued |
| LMAT LeMaitre Vascular, Inc. | $81.52 | $76.10 | -6.6% | Fairly valued |
| AVTR Avantor, Inc. | $15.25 | $18.06 | +18.4% | Undervalued |
All medical instruments & supplies stocks ranked by gap to fair value
Envista Holdings at a glance
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions.
- Market value
- $3.9B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $3.0B
- Consensus revenue growth, next fiscal year
- +5.9%
- Analysts with estimates
- 10
- Beta to the US market
- 1.10
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Envista Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 15 Aug 2026 the model's fair value for NVST was $32.50. As of 26 Sep 2026 it is $23.26, a change of -28.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Envista Holdings's valuation
Is Envista Holdings stock undervalued or overvalued?
Faircurve's model puts NVST's fair value at $23.26 a share against a last close of $23.95, as of 26 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is NVST's fair value?
$23.26 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $16.94 to $31.24.
What price range does the model give NVST?
$19.51 to $28.36 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
How confident is the model in this valuation?
Model confidence for NVST is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.